Trends in patient outcome over the past two decades following allogeneic stem cell transplantation for acute myeloid leukaemia: an ALWP/EBMT analysis

• DOI: 10.1111/joim.12854
• Publication Date: 2018-10-29T21:46:07Z
• Authors: J. Canaani; E. Beohou; M. Labopin; A. Ghavamzadeh; D. Beelen; R.‐M. Hamladji; D. Niederwieser; L. Volin; M. Markiewicz; R. Arnold; G. Mufti; G. Ehninger; G. Socié; N. Kröger; M. Mohty; A. Nagler
• Keywords: Cumulative incidence

Outcomes for patients with acute myeloid leukaemia (AML) undergoing allogeneic stem cell transplantation (allo-SCT) have significantly improved in recent years.To assess the incremental improvement of transplanted AML last two decades.Patients included this analysis were adult who underwent allo-SCT from an HLA-matched sibling donor (MSD) or unrelated (MUD) first remission. Patient outcomes assessed between three cohorts according to year transplant (1993-2002, 2003-2007 and 2008-2012).The comprised a total 20 187 whom 4763 1993 2002, 5835 2003 2007, 9589 2008 2012. In multivariate analysis, leukaemia-free survival (LFS) rates more recently compared 1993-2002 [Hazard ratio (HR) = 0.84, confidence interval (CI) 95%, 0.77-0.92; P 0.003], benefit which also extended overall (OS; HR 0.8, CI 0.73-0.89; < 0.0001), decreased nonrelapse mortality (NRM) (HR 0.65, 0.56-0.75; 0.0001). Subset revealed that MSD, LFS, NRM OS cohort similar results seen MUD. Finally, incidence graft-versus-host disease (GVHD) was reduced leading GVHD-free/relapse-free (GRFS) patients.Outcome has markedly decades owing resulting longer survival.